Matinas BioPharma Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.15
- Today's High:
- $0.1652
- Open Price:
- $0.15
- 52W Low:
- $0.11
- 52W High:
- $0.89
- Prev. Close:
- $0.157
- Volume:
- 437982
Company Statistics
- Market Cap.:
- $34.02 million
- Book Value:
- 0.128
- Revenue TTM:
- $3.22 million
- Operating Margin TTM:
- -704.35%
- Gross Profit TTM:
- $-13490000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -32.81%
- Return on Equity TTM:
- -58.47%
Company Profile
Matinas BioPharma Holdings Inc had its IPO on 2014-08-18 under the ticker symbol MTNB.
The company operates in the Healthcare sector and Biotechnology industry. Matinas BioPharma Holdings Inc has a staff strength of 34 employees.
Stock update
Shares of Matinas BioPharma Holdings Inc opened at $0.15 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.15 - $0.17, and closed at $0.16.
This is a +4.9% increase from the previous day's closing price.
A total volume of 437,982 shares were traded at the close of the day’s session.
In the last one week, shares of Matinas BioPharma Holdings Inc have slipped by -4.8%.
Matinas BioPharma Holdings Inc's Key Ratios
Matinas BioPharma Holdings Inc has a market cap of $34.02 million, indicating a price to book ratio of 3.5484 and a price to sales ratio of 64.488.
In the last 12-months Matinas BioPharma Holdings Inc’s revenue was $3.22 million with a gross profit of $-13490000 and an EBITDA of $-22303000. The EBITDA ratio measures Matinas BioPharma Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Matinas BioPharma Holdings Inc’s operating margin was -704.35% while its return on assets stood at -32.81% with a return of equity of -58.47%.
In Q2, Matinas BioPharma Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Matinas BioPharma Holdings Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Matinas BioPharma Holdings Inc’s profitability.
Matinas BioPharma Holdings Inc stock is trading at a EV to sales ratio of 50.926 and a EV to EBITDA ratio of -4.3379. Its price to sales ratio in the trailing 12-months stood at 64.488.
Matinas BioPharma Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $34.03 million
- Total Liabilities
- $2.59 million
- Operating Cash Flow
- $6.20 million
- Capital Expenditure
- $202000
- Dividend Payout Ratio
- 0%
Matinas BioPharma Holdings Inc ended 2024 with $34.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $34.03 million while shareholder equity stood at $27.85 million.
Matinas BioPharma Holdings Inc ended 2024 with $341000.00 in deferred long-term liabilities, $2.59 million in other current liabilities, 22000.00 in common stock, $-164204000.00 in retained earnings and $1.34 million in goodwill. Its cash balance stood at $9.74 million and cash and short-term investments were $22.51 million. The company’s total short-term debt was $613,000 while long-term debt stood at $0.
Matinas BioPharma Holdings Inc’s total current assets stands at $24.00 million while long-term investments were $0 and short-term investments were $12.77 million. Its net receivables were $0 compared to accounts payable of $604000.00 and inventory worth $0.
In 2024, Matinas BioPharma Holdings Inc's operating cash flow was $6.20 million while its capital expenditure stood at $202000.
Comparatively, Matinas BioPharma Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.16
- 52-Week High
- $0.89
- 52-Week Low
- $0.11
- Analyst Target Price
- $2.17
Matinas BioPharma Holdings Inc stock is currently trading at $0.16 per share. It touched a 52-week high of $0.89 and a 52-week low of $0.89. Analysts tracking the stock have a 12-month average target price of $2.17.
Its 50-day moving average was $0.27 and 200-day moving average was $0.45 The short ratio stood at 1.22 indicating a short percent outstanding of 0%.
Around 291.5% of the company’s stock are held by insiders while 1216.9% are held by institutions.
Frequently Asked Questions About Matinas BioPharma Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead’s antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.